Info Edge Ventures.
India's best-disclosed venture investor: ₹4,900 Cr deployed into 135 startups now marked ₹41,300 Cr: 8.4x gross, ~33% IRR, audited and published to shareholders. Zomato from a ₹9.4 Cr pre-money entry; Policybazaar from ₹21 Cr.
GW GP Score
Info Edge is the listed-company answer to venture opacity: as NSE-traded Naukri's investing arm, it publishes cost, mark and IRR for the whole book in shareholder letters. The record is generational: Zomato and Policybazaar entered at single-digit-crore pre-moneys are worth ₹31,500 Cr+, and the 2025-26 build-out is structural: Fund III (>₹2,000 Cr with Temasek), B8 growth fund, A88 deeptech fund, Redstart seed lab. The stated creed: 'long-term investors, not traders'. It did not sell a share of BlueStone, ixigo or Wakefit at their listings. The cost of that creed printed in Q4 FY26: ₹8,000 Cr+ of unrealised markdowns on Eternal and PB Fintech in one quarter.
Conditional hold: enough signal to track closely, not enough to underwrite without the next proof point.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
Eternal/PB Fintech mark trajectory after the Q4 FY26 ₹8,000 Cr+ swing.
Fund III final corpus with Temasek (>₹2,000 Cr expected).
Mark concentration: Eternal + PB Fintech are ~75%+ of FMV: one quarter took ₹8,000 Cr+ off.
Computed from current dossier sources; analyst override pending.
The best-documented compounding record in Indian venture, run from a listed balance sheet with radical disclosure. Concentration and the never-sell creed are the two risks the letters themselves acknowledge.
Zomato + Policybazaar are the two best venture entries in Indian history; broad younger book beneath
Marks are audited and liquid but deliberately unharvested; Shopkirana swap the rare exception
AI/deeptech/consumer themes with sovereign-AI adjacency (Gnani, LAT Aerospace)
Three new pools in 18 months; Temasek re-upping at every layer
Bikhchandani constant; Agarwal-led team stable since 2019
Portfolio quality 25% · Exit realisation 30% · Sector positioning 15% · Capital velocity 15% · Franchise stability 15%: see the full GP Score methodology · compare this firm →
Current evidence supports the score, but not enough to move it without a fresh exit, fund close or team signal.
BlueStone liquidity clears with credible OFS/block-sale evidence.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
Eternal/PB Fintech mark trajectory after the Q4 FY26 ₹8,000 Cr+ swing.
The shareholder letters are the closest thing India has to public DPI data: use their sleeve-level IRRs (consumer 34%, AI 31%, deeptech 15%) as your benchmark set when any GP claims outperformance.
Mark concentration: Eternal + PB Fintech are ~75%+ of FMV: one quarter took ₹8,000 Cr+ off.
Eternal/PB Fintech mark trajectory after the Q4 FY26 ₹8,000 Cr+ swing.
Coverage initiated: inaugural GW GP Score.
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 1 pressure catalyst(s); top driver: India PE-VC value down 5% YoY in H1 CY2026.
The broad private-capital backdrop is selective rather than euphoric; fundraising and mark support now need firm-specific proof.
Score pressureRaises the bar for weak-DPI managers and stale flagship vehicles; rewards funds with fresh closes or visible exits.
Separate broad PE-VC softness from venture AI strength before changing sector-positioning scores.
The funds
₹4,900 Cr deployed · marked ₹41,300 Cr (Mar 2026) across 4 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| IE Venture Fund III | 2025Recovery / IPO window | >₹2,000 Cr expected (w/ Temasek) | Early | Info Edge up to ₹1,000 Cr; shareholder-approved May 2025 |
| B8 Fund I / A88 Fund | 2026AI repricing | ₹250 Cr each | Growth / Deeptech | Both launched 2026: lifecycle build-out |
| IEVF I + II + Capital 2B | 2020-22Covid dislocation | ₹3,423 Cr corpus | Early + deeptech | Temasek matches ~50%; NAV ₹2,889 Cr at Dec 2024 |
| Balance sheet + Redstart | 2007-Foundation era | ~₹2,100 Cr | All | Zomato/PB Fintech vintage + wholly-owned deeptech lab |
Closest booksProsus Ventures (2 shared) · Peak XV Partners (2 shared) · Stride Ventures (1 shared)computed · E
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle closed inside the current exit/repricing window.
Next liquidityBlueStone · Shiprocket · Truemeds
1 visible exit events since Jul 2024.
Latest vehicle closed inside the current exit/repricing window.
5 up / 3 flat / 2 down tracked signals.
No senior departure flagged in key people.
5 up / 3 flat / 2 down
1 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Marked overhangEternal (Zomato) · PB Fintech (Policybazaar): names with negative 12-month mark or momentum signals in the reconstructed book.
Exit-led repricing; entry discipline decisive
Barbell market: AI premium vs everything else
Fear-priced entries: strong vintage in hindsight
Pre-unicorn pricing; discovery-cost entries
~3%: did NOT sell in the Aug 2025 IPO; company turned FY26-profitable
IPO pipeline
Follow-ons from Accel, Peak XV, WestBridge
At least one cited source is dated 2026.
1 visible events tracked.
10 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 2 · -1
Peer median 2 · +1
Peer median 74 · -4
Peer median 62 · -31
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
Exit data, Team data, Performance proxy evidence remains low-confidence despite a scored dossier.
Current · At least one cited source is dated 2026.
Upgrade the weak fields with dated facts before the next score action: Exit data, Team data, Performance proxy.
Prioritise filings and firm disclosures; mark estimates as GW E until then.
Fund III final corpus with Temasek (>₹2,000 Cr expected).
BlueStone: next public-market or secondary print
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Exit data, Team data, Performance proxy.
5 total sources · 40% primary
At least one cited source is dated 2026.
Info Edge: letter to shareholders (Jun 22, 2026)
Upgrade Exit data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
135 companies across six pools. 10 tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Eternal (Zomato) | Consumer & Commerce | 2010 | Seed (₹9.4 Cr pre-money) | Public | ▼ | 12.38% worth ~₹32,000 Cr; ₹5,874 Cr Q4 FY26 unrealised markdown; never trimmed since 2024 |
| PB Fintech (Policybazaar) | Fintech | 2008 | Seed (₹21 Cr pre-money) | Public | ▼ | ~19% incl. Makesense look-through; ₹5,200 Cr exceptional gain on merger reclassification FY26 |
| BlueStone | Consumer & Commerce | 2023 | Growth (₹150.6 Cr cost) | Public | ▲ | ~3%: did NOT sell in the Aug 2025 IPO; company turned FY26-profitable |
| ixigo | Consumer & Commerce | 2021 | ₹15 Cr (IEVF I) | Public | ▲ | Listed Jun 2024; unsold; Prosus now the big buyer on the register |
| Shiprocket | Logistics & Infra | 2020 | ₹111 Cr | Unicorn | → | IPO pipeline |
| Truemeds | Healthcare | 2020 | First cheque (₹97 Cr) | Soonicorn | ▲ | Follow-ons from Accel, Peak XV, WestBridge |
| Wakefit | Consumer & Commerce | 2022 | Capital 2B | Public | → | Listed Dec 2025: held |
| Gnani.ai | AI | 2022 | ₹40 Cr | Private | ▲ | ₹177 Cr IndiaAI GPU credits: sovereign-AI adjacency |
| Unbox Robotics | Deeptech & Space | 2020 | Redstart seed | Private | ▲ | Profitable swarm robotics: largest deeptech position |
| Adda247 | Consumer & Commerce | 2019 | ₹144 Cr | Private | → | Govt-exam edtech |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
29 cheques in 2025, 12 by mid-2026, plus two new vehicles launched: the fastest structural expansion in the cohort. Fund III's first cohort is AI-and-frontier-heavy (legal AI, genomics AI, aerospace, RF imaging), consistent with the published three-theme strategy.
Biostate, Jurisphere (legal AI), LAT Aerospace, Ulook, Climitra…
With Arkam, Accel
Realisation · are LPs getting paid?
Deliberately exit-averse: three portfolio listings in 24 months (BlueStone, Wakefit, ixigo) and zero OFS participation. The 36% balance-sheet IRR is real but overwhelmingly unrealised: Info Edge's discipline converts to shareholder value through its own listed stock, not distributions.
26.14% swapped to Udaan's parent Trustroot for $33M (mostly stock, ~2.1-2.3x INR, E): a rare exit, done as a swap, not cash.
Audited, in shareholder letters: no other Indian VC publishes this
45 companies, ₹2,755 Cr → ₹37,214 Cr
30 companies: young and honest about it
Eternal + PB Fintech dominate FMV; Q4 FY26 proved the swing
The transparency benchmark for the entire industry: cost, mark, IRR per sleeve, published twice a year. GW read: treat the 8.4x as concentration-driven (two 2008-10 seeds carry it) and the AIF-era 22% gross IRR as the true run-rate signal. E.
What they're doing
Full-lifecycle architecture: Redstart (seed deeptech) → Capital 2B/A88 (deeptech) → IEVF I-III (early) → B8 (growth).
Invest before consensus, hold through listing, prefer India-domiciled, IPO-exit companies.
Temasek as structural co-LP roughly matching Info Edge's commitments.
Radical disclosure as LP/shareholder currency: the letters ARE the fundraise.
What can break
Mark concentration: Eternal + PB Fintech are ~75%+ of FMV: one quarter took ₹8,000 Cr+ off.
Never-sell discipline means realisation risk compounds with public-market beta.
Deeptech and AI sleeves must eventually justify their own capital, not ride the consumer halo.
Eternal/PB Fintech mark trajectory after the Q4 FY26 ₹8,000 Cr+ swing.
Fund III final corpus with Temasek (>₹2,000 Cr expected).
First A88/B8 deployments.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
The shareholder letters are the closest thing India has to public DPI data: use their sleeve-level IRRs (consumer 34%, AI 31%, deeptech 15%) as your benchmark set when any GP claims outperformance.
Info Edge's cheque comes with Temasek matching and zero exit pressure, against it, you win on speed and ownership, never on patience. Its Fund III seed list is also a free map of what India's most patient investor thinks compounds for 12+ years.
Watch the new A88/B8 vehicles: where a never-sell investor builds dedicated deeptech and growth pools, it is underwriting a decade-long theme, not a cycle.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.